Viracta Therapeutics Inc (NASDAQ:VIRX)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - VIRX

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - VIRX

  • Market Cap$440.660m
  • SymbolNASDAQ:VIRX
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS92765F1084

Company Profile

Viracta Therapeutics Inc is a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma.

Latest VIRX news

Currently there for this company. Visit our news hub for other news .